EVAX — Evaxion A/S

Nasdaq · Health Care · Biotechnology · CIK 1828253 · Denmark
Last close
$4.11
Market Cap
$34.28M
52W High
$4.75
52W Low
$2.96
ADV30
31,490
Next earnings
Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1, a multi-component prophylactic vaccine targeting skin and soft tissue infections with S. aureus bacteria; EVX-B2 to target multi-component prophylactic vaccine against gonorrhea bacteria; EVX-B3 to target bacterial pathogen associated with repeated infections; and EVX-V1, a multi-component prophylactic vaccine candidate for cytomegalovirus. The company was formerly known as Evaxion Biotech A/S and changed its name to Evaxion A/S in May 2025. Evaxion A/S was incorporated in 2008 and is based in Horsholm, Denmark.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 0 -3,819,000 -3,629,000 23,642,000 18,440,000 10,435,000
Dec 2025 0 -4,052,000 -5,918,000 28,408,000 23,234,000 11,369,000
Sep 2025 7,492,000 3,023,000 4,618,000 29,737,000 10,572,000 13,138,000
Jun 2025 37,000 -4,340,000 -4,831,000 22,449,000 14,746,000 16,223,000

Balance + Analyst (yfinance extras)

Retained Earnings
$-126,244,000
Inventory
Receivables
$1,051,000
ST Investments
EBIT TTM
$-8,733,000
Pretax Income TTM
$-8,619,000
Interest Exp TTM
$-114,000
Analysts
4

Yahoo Snapshot (yfinance, live)

Total Revenue
$7,528,000
EBITDA
$-8,824,500
Free Cash Flow
Enterprise Value
$1,682,963,840
Total Cash
$18,440,000
Total Debt
$0
Shares Out
8,340,215
Trailing EPS
$-1.00
Book Value
$2.04
ROE
-82.9%
ROA
-23.5%
Div Yield

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 7,528,000 -9,234,000 -7,707,000 28,408,000 11,369,000 -6,625,000
Dec 2024 3,344,000 -14,732,000 -10,567,000 12,485,000 14,137,000 -12,940,000
Dec 2023 73,000 -22,197,000 -22,125,000 12,889,000 17,618,000 -17,691,000
Dec 2022 0 -25,264,000 -23,169,000 22,025,000 13,722,000 -25,774,000
Dec 2021

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$0.04

Peers — same industry

TickerNameMarket CapLastDaily %
TVGN Tevogen Bio Holdings Inc. $36.01M $8.60
ALGS Aligos Therapeutics, Inc. $30.93M $5.74
INMB Inmune Bio, Inc. $38.02M $1.43
ENZN Viskase Holdings, Inc. $38.02M $5.75
SNTI Senti Biosciences, Inc. $30.90M $0.99

News headlines (Yahoo Finance, 1h cache)

European Equities Traded in the US as American Depositary Receipts Open Week Tracking Higher in Monday Trading
2026-05-18 15:11 · Yahoo
European Equities Traded in the US as American Depositary Receipts Flat in Wednesday Trading
2026-05-13 15:12 · Yahoo
Evaxion to present new data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, at the EHA 2026 Congress
2026-05-12 13:30 · Yahoo
European Equities Traded in the US as American Depositary Receipts Rise Friday
2026-05-08 15:10 · Yahoo
Evaxion (EVAX) Q1 2026 Earnings Transcript
2026-05-07 19:42 · Yahoo
Evaxion announces business update and first quarter 2026 financial results
2026-05-07 11:30 · Yahoo
Evaxion to announce business update and first quarter 2026 financial results on May 7, 2026
2026-05-04 12:00 · Yahoo
Evaxion promotes Birgitte Rønø to joint role of Chief Scientific and Chief Operating Officer
2026-04-27 12:00 · Yahoo
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading
2026-04-24 15:23 · Yahoo
European Equities Traded in the US as American Depositary Receipts Edge Higher in Wednesday Trading
2026-04-22 15:13 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.